EGFR and non-small cell lung carcinoma: Osimertinib, a third-generation irreversible EGFR-TKI, has shown efficacy in advanced NSCLC patients harboring T790M, which is the most frequently acquired resistance mechanism after treatment with first-generation EGFR-TKIs [103,104,105].